Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Pulmonary Hypertension, January 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 235 articles: HTML format

Single Articles

1. LIU C, Lu JW, Wu CH, Ho YJ, et al
   Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes.
   In Vivo. 2026;40:551-560.
   Abstract
   
   
2. XU W, Shen Y, Wan Z, Guo J, et al
   Macrophage-driven immunopathology in pulmonary arterial hypertension: from mechanisms to targeted therapies.
   Front Immunol. 2025;16:1721071.
   Abstract
   
   
3. FERRARA F, Castaldo R, Gargani L, Benjamin N, et al
   Predicting Exercise Pulmonary Hypertension: The RIGHT-NET Machine Learning model A Pilot Study.
   Transl Res. 2025 Dec 30:S1931-5244(25)00121-5. doi: 10.1016/j.trsl.2025.
   Abstract
   
   
4. DESHMUKH SN, Anand A, Deore SS
   Haemodynamics and post-exercise recovery response in chronic obstructive pulmonary disease-pulmonary hypertension and interstitial lung disease-pulmonary hypertension: An appraisal.
   Lung India. 2026;43:105-106.
   Abstract
   
   
5. MALAKOUTIKHAH M, Kalantari F, Nematollahi A, Moradi H, et al
   Severe pulmonary hypertension associated with unilateral pulmonary artery hypoplasia: A case report.
   ARYA Atheroscler. 2025;21:1-7.
   Abstract
   
   
6. MARTINEZ-SOLANO J, Bermejo-Fernandez J, Gonzalez-Mansilla A, Garcia-Orta R, et al
   The role of the bone morphogenetic protein receptor 2 pathway in group 2 pulmonary hypertension secondary to valvular heart disease.
   ERJ Open Res. 2025;11:00543-2025.
   Abstract
   
   
7. J JB, R J, Murugan S, G SL, et al
   Identification of upregulated genes in pulmonary hypertension using RNA sequencing profiling.
   Bioinformation. 2025;21:3105-3109.
   Abstract
   
   
8. TITZ A, Muller J, Schneider SR, Lichtblau M, et al
   Comparison of Invasive Versus Non-Invasive Pulse Contour-Based Cardiac Output Measurements at Rest and During Exercise in Pulmonary Hypertension.
   J Clin Med. 2025;14:8971.
   Abstract
   
   
9. TITOLO AC, Ferrocino M, Biagi E, Rizzo L, et al
   Neonatologist-Performed Echocardiography in Neonatal Pulmonary Hypertension: A Narrative Review of the Literature.
   Diagnostics (Basel). 2025;15:3154.
   Abstract
   
   
10. HUANG W, Zheng R, Gong L, Zhang Y, et al
    Roles of Lipid Metabolism in Pulmonary Hypertension: Friend or Foe?
    Biomolecules. 2025;15:1679.
    Abstract
    
    
11. CSOMA B, Szucs G, Bikov A, Rozgonyi ZD, et al
    Alveolar and Bronchial Nitric Oxide Parameters in Pre-Capillary Pulmonary Hypertension.
    Biomedicines. 2025;13:2957.
    Abstract
    
    
12. WANG M, Lu J, Li X, Xie H, et al
    Construction of an early diagnostic model for pulmonary hypertension based on aging-related signature genes and identification of potential therapeutic targets.
    Sci Rep. 2025;15:44788.
    Abstract
    
    
13. LARSON J, Khorasani S, Laurenzo S, Chiu S, et al
    Leveraging Vascular Over Ventricular Ratios in Observational Chronic Thromboembolic Pulmonary Hypertension and Acute Pulmonary Embolism Cohorts to Decode Clot Chronicity on Computed Tomography Angiography.
    Pulm Circ. 2025;15:e70223.
    Abstract
    
    
14. SANTACRUZ JC, Mantilla MJ, Pulido S, Agudelo C, et al
    Pulmonary Hypertension in Systemic Lupus Erythematosus: Current Evidence and Future Directions.
    Cureus. 2025;17:e97863.
    Abstract
    
    
15. YAGDIRAN B, Uchehara CU, Safak A, Cekmen N, et al
    The relationship between preoperative pulmonary hypertension risk in liver transplant and vascular and biliary complications in the postoperative period.
    Diagn Interv Radiol. 2025 Dec 29. doi: 10.4274/dir.2025.253707.
    Abstract
    
    
16. PARLAK ES, Uzun BAA, Gungor K, Ceylan EG, et al
    Evaluation of Predisposing Factors and Coexisting Diseases in the Development of Chronic Thromboembolic Pulmonary Disease.
    Clin Respir J. 2025;19:e70147.
    Abstract
    
    
17. LIU Y, Deng X, He C, Lv S, et al
    NDRG1-HIF1alpha interaction in hypoxic signaling for pulmonary hypertension.
    Int J Biol Macromol. 2025;339.
    Abstract
    
    
18. DUBLE EH, Springer CM, Koster LS
    Association of pulmonary arterial end-diastolic forward flow and right heart remodeling in dogs with congenital pulmonic stenosis and precapillary pulmonary hypertension.
    J Vet Cardiol. 2025;64:14-24.
    Abstract
    
    
19. DZIKOWSKA-DIDUCH O, Dudzik-Niewiadomska I, Kurnicka K, Lichodziejewska B, et al
    Elevated tricuspid peak systolic gradient with enlarged right ventricle present during acute episode of pulmonary embolism predict subsequent chronic thromboembolic pulmonary hypertension.
    Thromb J. 2025 Dec 27. doi: 10.1186/s12959-025-00818.
    Abstract
    
    
20. JU G, Zhang S, Zhang J, Dong F, et al
    Sodium Houttuyfonate Alleviates Monocrotaline-induced Pulmonary Hypertension by Regulating Canonical Transient Receptor Potential Channel Proteins.
    Eur J Pharmacol. 2025 Dec 25:178507. doi: 10.1016/j.ejphar.2025.178507.
    Abstract
    
    
21. HE R, Liu J, Tang X, Liu H, et al
    Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy.
    Pediatr Res. 2025 Dec 26. doi: 10.1038/s41390-025-04720.
    Abstract
    
    
22. ZHANG Y, Zhang Y, Yang S, Huang Y, et al
    Risk prediction and therapeutic targets for incident pulmonary hypertension: a large-scale proteomic profiling and Mendelian randomization study.
    Front Med. 2025 Dec 27. doi: 10.1007/s11684-025-1183.
    Abstract
    
    
23. BUSCHULTE K, Kabitz HJ, Hagmeyer L, Hammerl P, et al
    Baseline characteristics from the EXCITING-ILD registry.
    BMJ Open Respir Res. 2025;12:e002902.
    Abstract
    
    
24. CHEN M, He Y, Zhu X, Luo Y, et al
    Baicalin attenuates pulmonary hypertension by targeting AMPK/CPT1A-mediated fatty acid metabolism.
    Phytomedicine. 2025;150:157703.
    Abstract
    
    
25. SONNICK MA, Laothamatas KC, Anderson MR, Stewart D, et al
    Waitlist outcome differences for pulmonary hypertension patients are worse in the CAS era.
    JHLT Open. 2025;11:100443.
    Abstract
    
    
26. MACIAS PRADO FE, German Gaibor JM, Portaluppi Cervantes RE, Campozano Burgos MA, et al
    Beyond Childhood: Percutaneous Closure of an Aortopulmonary Window with Severe Pulmonary Hypertension in an Adult Woman - A Case Report.
    Interv Cardiol. 2025;20:e34.
    Abstract
    
    
27. BEN DAVID R, Gurfinkel R, Nalbandyan K, Roth I, et al
    [Pulmonary Tumor Thrombotic Microangiopathy - Case Report].
    Harefuah. 2025;165:647-650.
    Abstract
    
    
28. KERRIGAN WJ, Church AC, Herrick AL
    Systemic Sclerosis-Recent Advances in Diagnosis and Management.
    Br J Hosp Med (Lond). 2025;86:1-21.
    Abstract
    
    
29. FUJIWARA M, Yamamura A, Miyaki R, Amano T, et al
    Enhanced Yoda1-induced vasoconstriction in pulmonary arterial smooth muscle from monocrotaline-induced pulmonary hypertensive rats.
    Biochem Biophys Res Commun. 2025;797:153183.
    Abstract
    
    
30. NEWMAN J, Ghani H, Munagala S, Otter E, et al
    The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients.
    ERJ Open Res. 2025;11:00297-2025.
    Abstract
    
    
31. GILLMEYER KR
    Insights from the Pulmonary Hypertension Global Patient Survey: challenges in pulmonary hypertension care abound but so do opportunities.
    ERJ Open Res. 2025;11:00963-2025.
    Abstract
    
    
32. JENKIN I, Dimopoulos K, Nathan SD, Herbert S, et al
    Survival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype.
    ERJ Open Res. 2025;11:00235-2025.
    Abstract
    
    
33. MICKAEL C, Kabwe JC, Fonseca Balladares D, Bai AS, et al
    Pulmonary Hypertension Associated With Sickle Cell Disease and Schistosomiasis.
    Pulm Circ. 2025;15:e70230.
    Abstract
    
    
34. LOKHANDWALA A, Salman Al-Timimi A, Da Silva T, Nourouzpour S, et al
    Clinical implications of frailty in hospitalized patients with pulmonary arterial hypertension.
    Chron Respir Dis. 2025;22:14799731251408844.
    Abstract
    
    
35. DAGHER C, Akiki M, Swanson K, Carollo B, et al
    Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy.
    Clin Respir J. 2025;19:e70149.
    Abstract
    
    
36. TAKITA Y, Morishita J, Park S, Goda A, et al
    Mindfulness-Based Self-Management Program Using a Mobile Application for Patients with Pulmonary Hypertension: A Single-Arm Feasibility Study.
    JMIR Cardio. 2025 Dec 16. doi: 10.2196/79639.
    Abstract
    
    
37. WANG X, He Y, Li K, Xue Z, et al
    TRAF6 mediates vascular remodeling via endoplasmic reticulum stress-mitophagy in hypoxic pulmonary hypertension.
    Free Radic Biol Med. 2025 Dec 20:S0891-5849(25)01448.
    Abstract
    
    
38. BEIS I, Dipla K, Haidich AB, Boutou A, et al
    Safety and efficacy of exercise training in patients with pulmonary hypertension: a systematic review and meta-analysis.
    Eur J Appl Physiol. 2025 Dec 22. doi: 10.1007/s00421-025-06104.
    Abstract
    
    
39. SEEGER W
    The Discovery of Inhaled Prostanoids for Pulmonary Hypertension.
    Pulm Circ. 2025;15:e70192.
    Abstract
    
    
40. LEE L, Cao S, Miles CB, Troy MP, et al
    Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Patient Selection, Procedural Pearls, and Expected Outcomes.
    Semin Intervent Radiol. 2025;42:509-517.
    Abstract
    
    
41. MERK J, Yung D, Wright JN, Kapur RP, et al
    Noncirrhotic Portopulmonary Hypertension Due to Hepatoportal Sclerosis in Adams-Oliver Syndrome.
    Pediatrics. 2026;157:e2025073243.
    Abstract
    
    
42. HU Y, Wang Y, Tan W, Zhao C, et al
    Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension.
    J Med Chem. 2025;68:26547-26573.
    Abstract
    
    
43. ZULFIQAR H, Alali J, Granlund B, Feng J, et al
    Interleukin-35 alleviates pulmonary arterial hypertension by suppressing the VEGFA/VEGFR2 signaling pathway.
    Life Sci. 2026;385:124144.
    Abstract
    
    
44. ZHANG JY, Zhang R, Liu J, Chen L, et al
    Agomelatine alleviates hypoxia-induced pulmonary arterial hypertension by activating mitophagy via the SIRT1/FoxO1/ULK1 signaling pathway.
    Biochem Pharmacol. 2026;244:117624.
    Abstract
    
    
45. WANG S, Song S, Feng H, Sun H, et al
    tRF-31-PS5P4PW3FJHP inhibits hypoxia-induced proliferation of pulmonary artery endothelial cells by regulating EDN1 splicing via binding to LSM4.
    Eur J Pharmacol. 2026;1011:178426.
    Abstract
    
    
46. ZOLTY R
    Antiproliferative therapies in pulmonary arterial hypertension.
    Expert Opin Pharmacother. 2025;26:1895-1911.
    Abstract
    
    
47. AHMAD A, Zhang S, Ren Q, Li L, et al
    Transthoracic echocardiography of left ventricular underfilling improves risk stratification in pulmonary arterial hypertension.
    Sci Rep. 2025;15:45718.
    Abstract
    
    
48. MOSS ME, Smit MC, Klouda T, Zhao Z, et al
    Pericytes and Lung Vascular Remodeling.
    Arterioscler Thromb Vasc Biol. 2026;46:17-26.
    Abstract
    
    
49. GARCIA KM, Hardie BA, Valdez-Jasso D
    Sex-Specific Interventricular Septum Mechanics in Pulmonary Arterial Hypertension.
    Ann Biomed Eng. 2026;54:29-40.
    Abstract
    
    
50. BETTER J, Leroy S, Ninaber MK, Trakada G, et al
    VE/VCO(2) at ventilatory threshold and peak VO(2) in CPET studies of patients with scleroderma-associated PAH: A systematic review and meta-analyses.
    Autoimmun Rev. 2026;25:103942.
    Abstract
    
    
51. SHI W, Chen L, Zhang W, He P, et al
    YAP-mediated glycolysis promotes pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension.
    J Biol Chem. 2025;301:110836.
    Abstract
    
    
52. HUANG Y, Zhang C, Ye H, Sun X, et al
    A Noninvasive Prognostic Model for Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases Based on Multislice Chest Computed Tomography Parameters.
    J Thorac Imaging. 2026;41:e0855.
    Abstract
    
    
53. ZHOU L, Luo J, Tan C, Li Y, et al
    Worldwide Burden of Pulmonary Arterial Hypertension in Adults Aged 65 Years and Older From 1990 to 2021.
    J Am Geriatr Soc. 2025;73:3700-3707.
    Abstract
    
    
54. TRUONG R, Davis S, Rosario N, Wollen J, et al
    Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment.
    Ann Pharmacother. 2026;60:163-174.
    Abstract
    
    
55. POST TE, Denney C, Cohen A, Jordan J, et al
    Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research.
    Br J Clin Pharmacol. 2026;92:58-72.
    Abstract
    
    
56. AKOPYAN K, Peterson J, Amoda O, Khasawneh M, et al
    Echocardiographic Pulmonary Hypertension in Patients Positive for Myositis-Specific and Myositis-Associated Antibodies.
    J Clin Med. 2025;15:77.
    Abstract
    
    
57. KOOK H, Kim W, Heo R, Kim K, et al
    Current Perspectives on Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
    J Clin Med. 2025;15:51.
    Abstract
    
    
58. ZHANG X, Chen M, Wang R, Liu R, et al
    Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.
    Int J Mol Sci. 2025;27:210.
    Abstract
    
    
59. IANCU DG, Cristescu L, Mares RG, Varga A, et al
    Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on "Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in
    Diagnostics (Basel). 2025;16:56.
    Abstract
    
    
60. PAGNONI G, Vicenzi A, Coppi F
    Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypert
    Diagnostics (Basel). 2025;16:55.
    Abstract
    
    
61. ADU-AMANKWAAH J, Shi Y, Song H, Ma Y, et al
    Correction: Signaling pathways and targeted therapy for pulmonary hypertension.
    Signal Transduct Target Ther. 2026;11:12.
    Abstract
    
    
62. ZHANG Y, Ye J, Chen J, Chen J, et al
    Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database.
    Cardiovasc Toxicol. 2026;26:12.
    Abstract
    
    
63. VACHRUSHEV NS, Karpov AA, Shilenko LA, Vaulina DD, et al
    Lung Tissue RNA Sequencing Shows Dysregulation of the Bronchial Epithelium in a Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
    Bull Exp Biol Med. 2026 Jan 9. doi: 10.1007/s10517-026-06549.
    Abstract
    
    
64. PRISCO SZ, Kantorovich A, Liu Y, Sahay S, et al
    Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream.
    Pulm Circ. 2026;16:e70229.
    Abstract
    
    
65. DAOUD A, Lopez PP, Mombeini H, Zaeske A, et al
    Echocardiographic Deformation Imaging of the Right Atrium: A New Paradigm in Noninvasive Hemodynamic Assessment.
    Curr Cardiol Rep. 2026;28:11.
    Abstract
    
    
66. KHAN SA, Parikh T, Rao A, Agrawal A, et al
    In-hospital Mortality Patterns and Readmissions in Patients With Chronic Obstructive Pulmonary Disease: An Analysis of the Role of Pulmonary Hypertension.
    COPD. 2026;23:2582902.
    Abstract
    
    
67. SHIMOJO T, Tada T, Ito H, Kinoshita H, et al
    Pulmonary tumour thrombotic microangiopathy or chronic thromboembolic pulmonary hypertension?-diagnosed by pulmonary wedge aspiration cytology using a Swan-Ganz catheter: a case report.
    Eur Heart J Case Rep. 2025;10:ytaf648.
    Abstract
    
    
68. ZHU Y, He J, Cai M, Wen L, et al
    Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study.
    Transl Pediatr. 2025;14:3305-3317.
    Abstract
    
    
69. MIRZAMOHAMMADI S, Shirazi N, Deravi N, Zadeh RH, et al
    Coronary Artery Calcium Score as a Potential Non-Invasive Marker for Pulmonary Artery Hypertension.
    Acta Med Indones. 2025;57:445-453.
    Abstract
    
    
70. WANG X, Song X, Yu F, Yu Y, et al
    A Superoxide Anion-Responsive NIR Fluorogenic Probe Unravels Aucubin's Dual-Axis Therapeutic Mechanism in Hypoxic Pulmonary Hypertension via Ferroptosis Suppression and Oxidative Injury Mitigation.
    Anal Chem. 2026 Jan 7. doi: 10.1021/acs.analchem.5c05233.
    Abstract
    
    
71. KONDOH Y, Ogura T, Nishiyama O, Kinoshita H, et al
    Corrigendum to "Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease" [Respir Invest, Volume 64, Issue 1, January 2026, 101340].
    Respir Investig. 2026 Jan 6:101365. doi: 10.1016/j.resinv.2025.101365.
    Abstract
    
    
72. SEERAM VK, Boppana LKT
    Unilateral absence of pulmonary artery presenting with pulmonary hypertension in two adults.
    BMJ Case Rep. 2026;19:e269028.
    Abstract
    
    
73. ARTHUR ME, Mudaliar P, Sakharpe A, Odo N, et al
    Between a Rock and a Hard Place: Hip Fracture Repair in an Elderly Patient with Severe Cardiac Comorbidities and Limited Options: A Problem-Based Learning Discussion.
    A A Pract. 2026;20:e02058.
    Abstract
    
    
74. VENKATESHVARAN A, Lindow T, Jumatate R, Kovacs A, et al
    Linking Energetic Inefficiency to Ventriculoarterial Uncoupling in Pulmonary Hypertension.
    Echocardiography. 2026;43:e70389.
    Abstract
    
    
75. HAO J, Fang G, Li X, Wang T, et al
    Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension.
    Hypertension. 2026 Jan 7. doi: 10.1161/HYPERTENSIONAHA.125.25832.
    Abstract
    
    
76. HUANG Y, Yan S, Zhu J, Zhang W, et al
    SPP1 May Play an Important Role in the Carcinoid Nature of PAH.
    Mediators Inflamm. 2025;2025:7457106.
    Abstract
    
    
77. PAK O, Weissmann N
    Is it the extracellular matrix?-smooth muscle fate in pulmonary hypertension secondary to left heart disease.
    Cardiovasc Res. 2026 Jan 7:cvaf261. doi: 10.1093.
    Abstract
    
    
78. LI G, Zhao Z, Machitani M, Ishikawa R, et al
    Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota.
    Biomed Pharmacother. 2026;194:118923.
    Abstract
    
    
79. YUE K, Qu X, Zhang F, Zhao M, et al
    Pulmonary hypertension caused by fibrosing mediastinitis: A case report and literature review.
    Medicine (Baltimore). 2026;105:e46180.
    Abstract
    
    
80. KIM TH, Youn SE, Chung SH
    Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study.
    Medicine (Baltimore). 2026;105:e46984.
    Abstract
    
    
81. BELKIN MN, Fudim M, Baratto C, Grinstein J, et al
    Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of Heart Failure and Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circ Heart Fail. 2026 Jan 6:e000088. doi: 10.1161/HHF.0000000000000088.
    Abstract
    
    
82. QIU Y, Lyu X, Zhang D, Xu H, et al
    Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues.
    Compr Physiol. 2026;16:e70094.
    Abstract
    
    
83. WANG Q, Liu J, Li R, Kong S, et al
    Macrophage kappa-opioid receptor inhibits hypoxic pulmonary hypertension progression and right heart dysfunction via an SCD1-dependent anti-inflammatory response.
    Genes Dis. 2025;13:101604.
    Abstract
    
    
84. WANG M, Zhang M, Chen J, Wang Y, et al
    Nuclear SIRT6 depletion activates LINE1-cGAS-STING pathway to induce PASMCs senescence in hypoxic pulmonary hypertension.
    Cell Signal. 2026;139:112351.
    Abstract
    
    
85. DING H, Zeng M, Sun B, Deng F, et al
    Measurement of Pulmonary Artery Pressure in Rats Using Right Heart Catheterization.
    J Vis Exp. 2025;.
    Abstract
    
    
86. BAHMANI F, Pearce D, Southern K, Nwadiaro K, et al
    Fluid Flow Analysis of Pulmonary Hypertension in End Stage Renal Disease: A NAMS-Driven Case Study.
    J Biomech Eng. 2026 Jan 5:1-29. doi: 10.1115/1.4070760.
    Abstract
    
    
87. HEGAZY Y, Abdallah A, Salem A, Assaker A, et al
    When the Skin Tells a Pulmonary Story: A Case of Neurofibromatosis Type 1-Associated Pulmonary Hypertension.
    Cureus. 2025;17:e98338.
    Abstract
    
    
88. KURAHARA LH
    [Cellular senescence in pulmonary hypertension].
    Nihon Yakurigaku Zasshi. 2026;161:55-56.
    Abstract
    
    
89. YOKOKAWA T, Nishiura K, Akama J, Kiko T, et al
    Significance of 14-3-3 Epsilon for Right Ventricular Failure Associated with Pulmonary Hypertension.
    Intern Med. 2026 Jan 2. doi: 10.2169/internalmedicine.6383.
    Abstract
    
    
90. NAEEM A, Bolaji O, Kidess GG, Fahed J, et al
    Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.
    Int J Cardiol. 2026;447:134150.
    Abstract
    
    
91. SOMECH J, Zahler D, St-Germain R, Roshdy O, et al
    Rapidly reversible precapillary pulmonary hypertension in a patient with scurvy.
    Can J Cardiol. 2026 Jan 2:S0828-282X(25)01621-6. doi: 10.1016/j.cjca.2025.
    Abstract
    
    
92. BARANYAI T, Takacs P, Szabo B, Nagy Z, et al
    [Balloon pulmonary angioplasty in Gottsegen National Cardiovascular Center - results of the first 2 years].
    Orv Hetil. 2026;167:23-29.
    Abstract
    
    
93. ROSHANZAMIR Z, Mohammadi F, Shirzadi R
    Pulmonary hypertension in pediatric patients with cystic fibrosis during acute pulmonary exacerbations: prevalence and associated factors.
    BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04095.
    Abstract
    
    
94. KAM THH, Kam KKH, Wong MKL, Yan BPY, et al
    Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study.
    BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04069.
    Abstract
    
    
95. HAN R, Wang Y, Lu X, Li W, et al
    Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration.
    Respir Res. 2026 Jan 3. doi: 10.1186/s12931-025-03446.
    Abstract
    
    
96. GUAN A, Dai Z, Lin J, Chen Q, et al
    Global disease burden of pulmonary arterial hypertension: patterns and inequality in 1990-2021, with projections to 2035.
    BMC Public Health. 2026;26:4.
    Abstract
    
    
97. LIU BY, Xie M
    [Application and research progress of artificial intelligence in the diagnosis and treatment of rare lung diseases].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:78-83.
    Abstract
    
    
98. MIHAI A
    Right Ventricular Global Wasted Work and RV-PA Coupling: Implications for Pulmonary Hypertension.
    Echocardiography. 2026;43:e70384.
    Abstract
    
    
99. SPAGNOLO P, Dhanani Z, Cameli P, Fiorentu G, et al
    Advanced Pulmonary Sarcoidosis.
    Semin Respir Crit Care Med. 2025;46:564-575.
    Abstract
    
    
100. QIAO X, Su D, Qin S, Shang L, et al
     Pulmonary arterial hypertension increases the risk of female sexual dysfunction: a systematic review and meta-analysis.
     J Sex Med. 2026;23:qdaf294.
     Abstract
     
     
101. ZHI C, Shi X, Chen S, Cai Z, et al
     Single-cell transcriptome analysis reveals critical causative candidates for Down syndrome-related lung diseases.
     J Genet Genomics. 2026;53:75-86.
     Abstract
     
     
102. MOU H, Zhang G, Xiu L, Zhao Q, et al
     AI-assisted multimodal assessment for right ventricular function from echocardiography predicts mortality in patients with pulmonary hypertension and right heart failure.
     Sci Rep. 2026 Jan 16. doi: 10.1038/s41598-026-36533.
     Abstract
     
     
103. HERRERA-LEANO N, Sahay S, Benza RL, Barahona-Correa J, et al
     Old Criteria, New Intelligence: The Evolution of ECG in Pulmonary Hypertension Diagnosis.
     Respir Med. 2026 Jan 14:108646. doi: 10.1016/j.rmed.2026.108646.
     Abstract
     
     
104. ZHANG J, Fan Y, Gao Y, Jin Y, et al
     Histone deacetylase 3 promotes hypoxia-induced human pulmonary arterial smooth muscle cell proliferation by modulating the CSF2-JAK2-STAT5 signaling pathway.
     Hum Cell. 2026;39:35.
     Abstract
     
     
105. CADD M
     Comment on "Intravenous Versus Inhaled Milrinone in Patients with Known Pulmonary Hypertension Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis".
     Ann Card Anaesth. 2026;29:150-151.
     Abstract
     
     
106. RASHID D, Zehra S
     Comment on "Intravenous Versus Inhaled Milrinone in Patients with Known Pulmonary Hypertension Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.
     Ann Card Anaesth. 2026;29:149-150.
     Abstract
     
     
107. GODINAS L, Orlitova M, Muscogiuri E, Ceulemans L, et al
     Lung transplantation for chronic thromboembolic pulmonary hypertension.
     JHLT Open. 2025;11:100461.
     Abstract
     
     
108. ZHANG P, Avazmohammadi R, Prins KW, Choudhary G, et al
     Mechano-energetic uncoupling in the right ventricle in pulmonary hypertension.
     JHLT Open. 2025;11:100460.
     Abstract
     
     
109. LUCERO MJ, Setua S, Thangaraju K, Khan A, et al
     Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice.
     Blood Adv. 2026 Jan 15:bloodadvances.2025018680.
     Abstract
     
     
110. PINTO OLIVEIRA C, Pascoal MD, Prata AR, Carvalho D, et al
     Comment on: Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient.
     Clin Exp Rheumatol. 2026 Jan 12. doi: 10.55563.
     Abstract
     
     
111. ABOLWAFA A, Al-Lawati A, Al-Kindi HN, Zacharias S, et al
     Surgical Strategies for Unilateral Pulmonary Artery Agenesis: A case series.
     Sultan Qaboos Univ Med J. 2025;26:13-19.
     Abstract
     
     
112. ALIYAR AA, Eldar AS, Sadig SA, Mubariz GT, et al
     Advances in the Study of Bronchial and Vascular Architecture of Lungs in the Rat's Model: from Morphogenesis to Disease Modelling.
     Cell Physiol Biochem. 2025;59.
     Abstract
     
     
113. YANG Y, Zhang Y, Gong S, Liang N, et al
     Pulmonary neuroendocrine cell as a therapeutic strategy in pulmonary hypertension: Great expectations or Bleak House?
     Life Sci. 2026;388:124194.
     Abstract
     
     
114. LIU K, Peng W, Yang X, Zeng Y, et al
     Efficacy and Multi-Omics Regulatory Effects of Guilou Tongluo Formula in Patients with Chronic Obstructive Pulmonary Disease Combined with Pulmonary Hypertension: A Prospective, Multicenter, Randomized Controlled Trial.
     J Ethnopharmacol. 2026 Jan 12:121204. doi: 10.1016/j.jep.2026.121204.
     Abstract
     
     
115. KLOUDA T, Wong W, Fynn-Thompson F, Esch JJ, et al
     Lung Transplantation and Reverse Potts Shunt for Pulmonary Hypertension in the Pediatric Population.
     Pediatr Transplant. 2026;30:e70263.
     Abstract
     
     
116. MENDES-FERREIRA P, Tielemans B, Wagenaar A, Bouzin C, et al
     Beta-3 Adrenoreceptor Agonist Mirabegron Improves Right Ventricular Function in a Rat Monocrotaline-Induced Pulmonary Hypertension Model.
     Pulm Circ. 2026;16:e70232.
     Abstract
     
     
117. YUE X, Lan J, Yang L, Zhao L, et al
     Curcumin-Loaded Tetrahedral Framework Nucleic Acids Alleviate Pulmonary Hypertension by Regulating Multiple Synergistic Signaling Pathways.
     Adv Healthc Mater. 2026 Jan 13:e05281. doi: 10.1002/adhm.202505281.
     Abstract
     
     
118. LI Y, Xing H, Liu Y, Li F, et al
     Roles of the Altitude-Adapted Immune Microenvironment in Pulmonary Vascular Remodeling in High-Altitude Pulmonary Hypertension: A Review.
     Med Sci Monit. 2026;32:e949962.
     Abstract
     
     
119. LAKEW YB, Ahmed HY, Mulisa MD, Arega B, et al
     Prevalence of pulmonary hypertension and its associated factors among chronic kidney disease patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: an institution-based retrospective study.
     BMC Cardiovasc Disord. 2026 Jan 13. doi: 10.1186/s12872-026-05516.
     Abstract
     
     
120. KAYSIN A, Swami S, Aluko O, Bultman DS, et al
     Topics in Lung Disease: Pulmonary Hypertension.
     FP Essent. 2025;559:7-15.
     Abstract
     
     
121. LIU A, Du J, Li H, Xi L, et al
     What is the difference between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension on phase-resolved functional lung MRI? A cross-sectional observational study.
     Eur Radiol. 2026 Jan 13. doi: 10.1007/s00330-025-12271.
     Abstract
     
     
122. LI J, Han P, Zhao X, Lan L, et al
     Echocardiographic Analysis of Tricuspid Regurgitation and Other Hemodynamic Factors in Relation to Right Atrial Function in Patients With Chronic Thromboembolic Pulmonary Hypertension.
     Echocardiography. 2026;43:e70393.
     Abstract
     
     
123. GUPTA S, Chopra D
     Do Nails Tell a Pulmonary Tale? A Cross-Sectional Study on Psoriasis and Pulmonary Hypertension Risk.
     J Cutan Med Surg. 2026 Jan 12:12034754251408375. doi: 10.1177/12034754251408375.
     Abstract
     
     
124. GIAKAS AM, Milano ME, Gehret JA, Rihn JA, et al
     Compressive cervicothoracolumbar epidural haematoma following lead insertion for spinal cord stimulator trial.
     BMJ Case Rep. 2026;19:e268333.
     Abstract
     
     
125. ZHANG J, Zhang W, Fan B, Yang Z, et al
     Paeoniflorin Alleviates Pulmonary Arterial Hypertension by Suppressing TRIM24-Mediated SIRT1 Ubiquitination and NLRP3 Inflammasome Activation.
     Chem Biol Drug Des. 2026;107:e70238.
     Abstract
     
     
126. SHARMA A, Bilal Y, Yousaf I, Masuta P, et al
     Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis.
     Cureus. 2025;17:e98767.
     Abstract
     
     
127. BISCOTTI RODIL B, Duarte Torres J, Martin De Miguel I, Cruz Utrilla A, et al
     Chronic Thromboembolic Pulmonary Hypertension Incidence, Post-pulmonary Embolism Syndrome and Possible Role of Transcatheter Therapy in Prevention.
     Interv Cardiol. 2025;20:e37.
     Abstract
     
     
128. ZHAO Y, Wang J, Qiao Y, Gai X, et al
     Echinacoside Improves Pulmonary Vascular Remodeling by Regulating the L- and T-Type Ca(2+) Channels in the Prevention and Treatment of Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70235.
     Abstract
     
     
129. CHEN A, Yan Y, Cao R, Cai K, et al
     Zinc-Induced PKCdelta-dependent Phosphorylation of MTF-1 Promotes Pulmonary Vascular Remodeling in Hypoxic Pulmonary Hypertension.
     Int J Biol Sci. 2026;22:823-840.
     Abstract
     
     
130. YUAN W, Tie H, Feng T, Zhang F, et al
     Successful surgical intervention for Berry syndrome combined with severe pulmonary hypertension: a case description.
     Quant Imaging Med Surg. 2026;16:100.
     Abstract
     
     
131. TSOI SM, Parker C, Colglazier E, Cheung S, et al
     The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension.
     Pediatr Pulmonol. 2026;61:e71448.
     Abstract
     
     
132. ZHAO L, Liu Y, Ou Z, Zhao X, et al
     GLP-1 agonists reduce right ventricular mitochondrial dysfunction by inhibiting the GSK3beta-Drp1 signalling in pulmonary hypertension.
     Eur J Med Res. 2026 Jan 10. doi: 10.1186/s40001-025-03815.
     Abstract
     
     
133. CHEN J, Chen Y, Chen W, Tan Y, et al
     Set7 regulates ferroptosis in pulmonary arterial hypertension endothelial cells through the DPP4/NOX4 axis mediated by H3K4me1 modification.
     Cell Signal. 2026;139:112352.
     Abstract
     
     
134. 
     [Guidelines for the diagnosis and treatment of pulmonary arterial hypertension associated with adult congenital heart disease].
     Zhonghua Xin Xue Guan Bing Za Zhi. 2026;54:9-38.
     Abstract
     
     
135. CHEN X, Yan D, Liu C, Dai J, et al
     The trend analysis and comparison of pulmonary arterial hypertension disease burden in China and India from 1990 to 2021: a study based on the Global Burden of Disease 2021 database.
     Eur J Med Res. 2025;31:78.
     Abstract
     
     
136. CETINKAYA C, Sagir A, Terzi A, Ermerak NO, et al
     Sclerotherapy embolism: a novel etiology for chronic thromboembolic pulmonary disease.
     BMC Pulm Med. 2025;26:14.
     Abstract
     
     
137. ZHU Y, Wang X, Yan X, Sun Y, et al
     Identification of potential biomarkers associated with mitochondrial oxidative stress in idiopathic pulmonary arterial hypertension via bioinformatic and experimental analysis.
     Sci Rep. 2025;16:1647.
     Abstract
     
     
138. ISHIHARA T, Kawamura G, Nagano M, Azuma S, et al
     Successful use of methylene blue for severe vasoplegia in a patient with partially-treated portopulmonary hypertension with atrial septal defect undergoing liver transplantation: a case report.
     BMC Anesthesiol. 2025;26:30.
     Abstract
     
     
139. HUANG AP, Voskamp S, Ebadi AA, Liedel JL, et al
     Meta-analysis of differential gene expression in idiopathic pulmonary arterial hypertension.
     Cardiovasc Pathol. 2026;81:107805.
     Abstract
     
     
140. WANG X, Li S, Hou J, Cao S, et al
     tsRNA-3040b accumulates R-loop to regulate Trim35 transcription, which leads to disordered glycolysis and promotes PAECs proliferation.
     Cell Mol Biol Lett. 2025;31:4.
     Abstract
     
     
141. PRABHAKAR A, De Bie EM, DesJardin JT, Ghatpande P, et al
     GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension.
     J Clin Invest. 2025;136:e199159.
     Abstract
     
     
142. SEEDAHMED MI, Okereke J, Al-Qadi MO
     Pulmonary hypertension in a distinct IgG4-high phenotype of sarcoidosis: A case series.
     J Natl Med Assoc. 2026 Jan 22:S0027-9684(25)00363.
     Abstract
     
     
143. CUETO-ROBLEDO G, Graniel-Palafox LE, Roldan-Valadez E
     Pulmonary Hypertension Unmasking Unilateral Absence of the Pulmonary Artery in Congenital Scoliosis.
     Mayo Clin Proc. 2026 Jan 23:S0025-6196(25)00507.
     Abstract
     
     
144. LIU G, Tian H, Tan J, Liu Y, et al
     Resistin-Like Molecule Beta Participates in Calcium Regulation Via Direct Interaction With CaSR and a PLC-IP(3)R-Dependent Mechanism in Hypoxia-Induced Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70247.
     Abstract
     
     
145. ALNASSER TN, Hokmabadi A, Checkley EW, Sharkey MJ, et al
     A fully automated explainable predictive model for diagnosing pre-capillary and post-capillary pulmonary hypertension on routine unenhanced CT: results from the ASPIRE registry.
     Eur Heart J Digit Health. 2025;7:ztaf124.
     Abstract
     
     
146. DOTEGUCHI S, Matsugi E, Takashima S, Kawai R, et al
     Influence of Patient Characteristics on the Effectiveness of Inhaled Nitric Oxide Therapy for Pulmonary Hypertension Following Cardiac Surgery: A Post-marketing Surveillance in Japan.
     Cureus. 2025;17:e99788.
     Abstract
     
     
147. YU Z, Chen Y, Zhang M, Feng N, et al
     Risk of Group 2 Pulmonary Hypertension in Newly Diagnosed Heart Failure: An EHR-Based Cohort Analysis.
     medRxiv [Preprint]. 2025 Dec 9:2025.12.03.25341274.
     Abstract
     
     
148. CAI C, Ni G, Chen L, Deng C, et al
     Altitude hypoxia and hypoxemia: pathogenesis and management.
     Signal Transduct Target Ther. 2026;11:27.
     Abstract
     
     
149. BIONDI F, Ghelardoni S, Morrone D, De Caterina R, et al
     Exercise pulmonary hypertension in chronic thromboembolic pulmonary disease without resting pulmonary hypertension: A systematic review and meta-analysis.
     Vascul Pharmacol. 2026 Jan 20:107580. doi: 10.1016/j.vph.2025.107580.
     Abstract
     
     
150. ADRIAN RJ, Eke OF, Al Jalbout N, Al Hariri M, et al
     Pulmonary hypertension in cardiac tamponade: An observational cohort study of in-hospital mortality and echocardiographic findings.
     Am J Emerg Med. 2026;102:55-61.
     Abstract
     
     
151. HERTIG D, Lichtblau M, Furian M, Ulrich S, et al
     [Acute high-altitude illnesses - Definition, Prophylaxis, Therapy].
     Ther Umsch. 2025;82:209-214.
     Abstract
     
     
152. YAMADA Y, Satoh T, Yaoita N, Yamada K, et al
     Pathogenesis of Pulmonary Artery Remodeling: TGF-Beta Signaling and Inhibin Subunit Beta A in Group 1 and 2 Pulmonary Hypertension.
     Arterioscler Thromb Vasc Biol. 2026 Jan 22. doi: 10.1161/ATVBAHA.125.322506.
     Abstract
     
     
153. LIU J, Hou L, Yang J, Xu Z, et al
     Development and Characterization of a Novel Chronic Thromboembolic Pulmonary Hypertension Rat Model: Identifying Sell-Podxl as Potential Regulators.
     Hypertension. 2026 Jan 22. doi: 10.1161/HYPERTENSIONAHA.125.25589.
     Abstract
     
     
154. IANNONE C, Stano S, Pellico MR, Cito A, et al
     Forced vital capacity as a survival predictor in systemic sclerosis-associated pulmonary hypertension.
     Ther Adv Musculoskelet Dis. 2026;18:1759720X251410681.
     Abstract
     
     
155. BECHER C, Groeneveld EJ, Quarck R, Neep B, et al
     BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension.
     Hypertension. 2026;83:e24916.
     Abstract
     
     
156. JANKAUSKAS SS, Kansakar U, Varzideh F, Santulli G, et al
     IL-33 Drives Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension.
     Hypertension. 2026;83:e26356.
     Abstract
     
     
157. CHEONG AP, Lam LT, Ng LH, Luk NHV, et al
     Pulmonary Artery Denervation With Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation and Pulmonary Hypertension.
     JACC Case Rep. 2026 Jan 2:106577. doi: 10.1016/j.jaccas.2025.106577.
     Abstract
     
     
158. DAGHER C, Thomas A, Al Absi S, Carollo B, et al
     Rapid Inpatient Uptitration of Inhaled Treprostinil in PH-ILD Patients with Severe Phenotype.
     Adv Respir Med. 2026;94:7.
     Abstract
     
     
159. TOCCI G, Santi M, Viola C, Pancani R, et al
     Stress testing in the diagnosis and early screening of chronic thromboembolic pulmonary disease with and without pulmonary hypertension.
     Eur J Clin Invest. 2026;56:e70175.
     Abstract
     
     
160. RIZZO C, La Barbera L, Guggino G
     Reply to the comment on: Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient.
     Clin Exp Rheumatol. 2026 Jan 20. doi: 10.55563.
     Abstract
     
     
161. SHYLLESH H A, Memon TA, Guruswamy P, Shekha TAM, et al
     Pulmonary Alveolar Microlithiasis Coexisting With Rheumatic Heart Disease and Severe Pulmonary Hypertension: A Case Report.
     Cureus. 2025;17:e99674.
     Abstract
     
     
162. CHEN R, Ye W, Yang Y, Liao H, et al
     Role of hsa-miR-122-5p in chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease: Targeting PIK3CG in the PI3K/Akt signaling pathway.
     Medicine (Baltimore). 2026;105:e47210.
     Abstract
     
     
163. CATALANI F, Valeriani E, Ageno W, Campello E, et al
     Anticoagulation in chronic thromboembolic pulmonary hypertension: an updated systematic review and meta-analysis.
     Intern Emerg Med. 2026 Jan 20. doi: 10.1007/s11739-025-04257.
     Abstract
     
     
164. UPHUS JAG, Hu JR, Huang S, Hofbauer TM, et al
     Prognostic Value of Acute Vasoreactivity in Chronic Thromboembolic Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70246.
     Abstract
     
     
165. SATOH A, Soyama A, Matsushima H, Kinoshita A, et al
     Liver Transplantation for a Patient With Hemophilia and HIV/HCV Coinfection Complicated by Pulmonary Hypertension.
     Hepatol Res. 2026 Jan 19. doi: 10.1111/hepr.70121.
     Abstract
     
     
166. CUI XH, Yu LL, Yang M, Liu W, et al
     Serum metabolomic profiles linking diabetes mellitus to pulmonary hypertension: a prospective cohort study with mediation analysis and risk prediction.
     Respir Res. 2026 Jan 19. doi: 10.1186/s12931-026-03499.
     Abstract
     
     
167. WREN JT JR, Joshi R, McNamara PJ
     Navigating the Unique Challenge of Pulmonary Hypertension From Left-to-Right PDA Shunts in Two Cases of Congenital Diaphragmatic Hernia.
     Echocardiography. 2026;43:e70396.
     Abstract
     
     
168. ZHANG Z, Zhang X, Duan F, Song Z, et al
     Efficacy and prognosis of multimodal angiography-interventions for chronic pulmonary artery stenosis and pulmonary hypertension.
     Am J Transl Res. 2025;17:9956-9967.
     Abstract
     
     
169. HERNANDEZ M, Winicki NM, Puerta CD, Lakshminarayanan S, et al
     The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension.
     Nat Med. 2026;32:306-317.
     Abstract
     
     
170. MA C, Wang Z, Zhu X, Pang X, et al
     Super enhancer-driven LINC01013 mediates hypoxia-induced mitochondrial dysfunction by HSPA9 to determine pulmonary arterial smooth muscle cell fate.
     Cell Mol Life Sci. 2026;83:57.
     Abstract
     
     
171. MORGAN C, Southgate L, Calder A, Sekar T, et al
     SOX17 variants are associated with severe pulmonary arterial hypertension with and without congenital heart disease.
     Int J Cardiol. 2026;447:134114.
     Abstract
     
     
172. ALSALEH T, Harb A, Chapagain P, Dakkak B, et al
     Prevalence and risk factors of portopulmonary hypertension in chronic liver disease: systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2026;50:102748.
     Abstract
     
     
173. FERNANDEZ VALLONE V, Fischer K, Kuchler J, Diekmann F, et al
     Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene.
     Stem Cell Res. 2026;90:103886.
     Abstract
     
     
174. LI P, Zhang B, Wang J, Li W, et al
     XLOC_010588 Promotes Mitophagy Via BAG2-Mediated PINK1 Stabilization in HPH.
     Hypertension. 2026;83:e25742.
     Abstract
     
     
175. FREYALDENHOVEN KJ, Johnson JA, Terrazas A, Alsaloum P, et al
     Cardiopulmonary Outcomes in Sarcoidosis Patients with Ocular Involvement: A Propensity-Score-Matched Analysis.
     Ocul Immunol Inflamm. 2026;34:64-72.
     Abstract
     
     
176. TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
     Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort.
     J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
     Abstract
     
     
177. CHILINGARASHVILI G, Mylvaganam RJ, Bernardo RJ, Shah A, et al
     Sotatercept in Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension: A Case Series and Systematic Review.
     Pulm Circ. 2026;16:e70239.
     Abstract
     
     
178. ALTURAIF N, Alduraibi FK, Marquez K, Alahmadi F, et al
     Pulmonary endarterectomy in antiphospholipid syndrome: a retrospective analysis from the Saudi pulmonary hypertension registry.
     Front Med (Lausanne). 2026;13:1736115.
     Abstract
     
     
179. KRONBERGER C, Mousavi RA, Ermolaev N, Poledniczek M, et al
     Performance on the one-minute sit-to-stand test predicts long-term adverse outcomes in pulmonary hypertension.
     Sci Rep. 2026 Jan 29. doi: 10.1038/s41598-026-37611.
     Abstract
     
     
180. BERTHELOT E, Bauer F, Fauvel C, Paclot M, et al
     Echocardiographic Risk Stratification in Heart Failure with Post-Capillary Pulmonary Hypertension: Prognostic Value of LAVI and TAPSE/PASP.
     Eur Heart J Cardiovasc Imaging. 2026 Jan 30:jeag034. doi: 10.1093.
     Abstract
     
     
181. PAGNONI G, Vicenzi A, Coppi F
     Designing the right trial for sacubitril / valsartan in heart failure with preserved ejection fraction-related pulmonary hypertension.
     Pol Arch Intern Med. 2026;136:17211.
     Abstract
     
     
182. NIEMIEC M, Grabka M, Niemiec R, Filipecki A, et al
     Designing the right trial for sacubitril / valsartan in heart failure with preserved ejection fraction-related pulmonary hypertension. Authors' reply.
     Pol Arch Intern Med. 2026;136:17212.
     Abstract
     
     
183. AHMED F, Haider F, Ali R, Arham M, et al
     Comparative accuracy of artificial intelligence versus manual interpretation in detecting pulmonary hypertension across chest imaging modalities: a diagnostic test accuracy meta-analysis.
     Front Artif Intell. 2026;8:1709489.
     Abstract
     
     
184. KUMAR P, Verma AK, Bajpai J, Kar SK, et al
     Pulmonary hypertension in patients with obstructive sleep apnea: Correlation with disease severity and quality of life.
     World J Cardiol. 2026;18:112541.
     Abstract
     
     
185. BAISYA R, Vardhan YK, Gsr M, Vardhan YV, et al
     The Long-Term Outcomes of Pulmonary Hypertension in Systemic Lupus Erythematosus (SLE-PAH) Vary Among Different Autoantibody-Based Clusters: An Observational, Longitudinal Study Conducted at a Single Centre in India.
     Mediterr J Rheumatol. 2025;36:594-599.
     Abstract
     
     
186. VENKATESHVARAN A, Lindqvist P, Evaldsson AW
     Right Ventricular Global Wasted Work: Employing Myocardial Energetics for Risk Assessment and Outcome Prediction in Pulmonary Hypertension.
     Eur Heart J Cardiovasc Imaging. 2026 Jan 28:jeag029. doi: 10.1093.
     Abstract
     
     
187. RONG C, Zhang L, Li B, Wang Y, et al
     Efficacy and safety of specific treatment combined with SGLT2-i in pulmonary hypertension.
     Front Cardiovasc Med. 2026;12:1684394.
     Abstract
     
     
188. WANG H, Cui M
     Effects of balloon pulmonary angioplasty on cardiac and pulmonary functions and complications in patients with chronic thromboembolic pulmonary hypertension.
     Front Med (Lausanne). 2026;12:1689193.
     Abstract
     
     
189. SHEN T, Lv X, Wang C, Ma Q, et al
     Severe pulmonary edema after pulmonary hypertension interventional surgery: case report and literature review.
     Front Med (Lausanne). 2026;12:1723147.
     Abstract
     
     
190. SUEBLINVONG V, Chang SS, Ma J, Archer DR, et al
     Long Non-Coding RNA MALAT1 Regulates HMOX1 in Sickle Cell Disease-Associated Pulmonary Hypertension.
     Cells. 2026;15:154.
     Abstract
     
     
191. TILEA I, Iancu DG, Fira-Mladinescu O, Bertici N, et al
     Sotatercept in Pulmonary Arterial Hypertension: Molecular Mechanisms, Clinical Evidence, and Emerging Role in Reverse Remodelling.
     Int J Mol Sci. 2026;27:767.
     Abstract
     
     
192. BATUM O, Ayik Turk M, Varol Y, Ozyilmaz B, et al
     Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism.
     Int J Mol Sci. 2026;27:758.
     Abstract
     
     
193. SCAGLIOLA R
     Deciphering the Counterintuitive Role of Vascular Endothelial Growth Factor Signaling Pathways in Pulmonary Arterial Hypertension.
     Int J Mol Sci. 2026;27:687.
     Abstract
     
     
194. MILANO G, Ottolenghi S, Zubieta-Calleja G, Beghetti M, et al
     Mechanisms Underlying Altitude-Induced and Group 3 Pulmonary Hypertension.
     Int J Mol Sci. 2026;27:572.
     Abstract
     
     
195. YOKOYAMA YM, Watanabe R, Yamaguchi T, Ishihara R, et al
     Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects.
     Biomolecules. 2026;16:140.
     Abstract
     
     
196. OKECHUKWU A, Odetunde O, Uchenna E, Chinawa JM, et al
     Prevalence and severity of persistent pulmonary hypertension of the newborns among asphyxiated neonates admitted in Enugu State University Teaching Hospital.
     BMJ Paediatr Open. 2026;10:e004351.
     Abstract
     
     
197. AHMADIPOUR B, Pat S, Khajali F, Hassanpour H, et al
     Effects of Sodium Butyrate Forms on Carcass Performance, Pulmonary Hypertension, Metabolic Health and Oxidative-Inflammatory Responses in Broiler Chickens Under Cold Stress at High Altitude.
     Vet Med Sci. 2026;12:e70720.
     Abstract
     
     
198. LIANG S, Wang X, Wu Y
     Establishment of a rat model of bronchopulmonary dysplasia complicated with pulmonary hypertension and its potential applications.
     Hum Exp Toxicol. 2026;45:9603271261420421.
     Abstract
     
     
199. GARCIA SM, Lantz BJ, Wagner HJ, Jones DT, et al
     Inducible Ift88-deficient mice show features consistent with mild pulmonary hypertension.
     Physiol Rep. 2026;14:e70749.
     Abstract
     
     
200. LECHUGA CG, Kachabi A, Colebank MJ, Korcarz CE, et al
     Patient-Specific Lumped-Parameter Model for Quantifying Vessel-Specific Remodeling and Predicting Right Ventricular Function in Pulmonary Hypertension.
     Compr Physiol. 2026;16:e70102.
     Abstract
     
     
201. ZHANG H, Guo X, Han Y
     A tale of two forces: pulmonary hypertension and hepatopulmonary syndrome in congenital portosystemic shunt.
     Eur Heart J. 2026 Jan 13:ehaf820. doi: 10.1093.
     Abstract
     
     
202. HUANG Y, Qin B, Shen B, Zhu J, et al
     Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: A Comparative Study of Biomarkers and Clinical Indicators.
     Pulm Circ. 2026;16:e70228.
     Abstract
     
     
203. SU H, Li B, Guo Z, Zhang F, et al
     Beta-Alanine Supplementation Ameliorates Right Ventricular Remodeling Caused by Monocrotaline-Induced Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70244.
     Abstract
     
     
204. MA J, Cao X, Yang X, Zhu Y, et al
     Natural products targeting the immune-metabolic regulatory network in pulmonary hypertension: mechanisms, classification, and therapeutic prospects.
     Front Pharmacol. 2026;16:1712903.
     Abstract
     
     
205. LU Z, Zhang C, Wan J, Xiao Y, et al
     Exercise tolerance in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty.
     Heart Lung. 2026;78:102725.
     Abstract
     
     
206. YOKAWA K, Kawakami M, Tanaka Y, Higuma T, et al
     Acute pulmonary hypertension induced by heparin-protamine complex during thoracoabdominal aortic grafting.
     J Cardiothorac Surg. 2026 Jan 24. doi: 10.1186/s13019-025-03807.
     Abstract
     
     
207. REVENKO SV, Tarakanov IA, Tikhomirova LN, Kuropatkina TA, et al
     Effect of Hindlimb Denervation on Survival Rate and Circulation and Respiration Systems in Monocrotaline Rat Model of Pulmonary Arterial Hypertension.
     Bull Exp Biol Med. 2025;179:644-649.
     Abstract
     
     
208. CHEN H, Qiu YX, Xie YF, Chen X, et al
     Redox switch C674 in SERCA2 triggers Ca(2+)-calcineurin-MCU-Drp1 cascade and pulmonary vascular remodeling.
     Free Radic Biol Med. 2026;244:380-394.
     Abstract
     
     
209. YU L, Hou Z, Han L, An Y, et al
     Clinical and imaging characteristics of pulmonary artery dissection.
     Int J Cardiovasc Imaging. 2026;42:111-117.
     Abstract
     
     
210. OU L, Chen Y, Shen A, He S, et al
     Epigenetically activated MIR100HG regulates UPF1-mediated oxidative stress to promote pulmonary vascular immune microenvironment remodeling.
     Free Radic Biol Med. 2026;244:210-228.
     Abstract
     
     
211. JIAO Q, Yang Y, Xu X, Hao J, et al
     Therapeutic potential of magnesium diboride nanosheets in PAH-associated right heart failure: Integrated multi-omics analysis reveals ferroptosis suppression via LC3/ATG5/NCOA4/FTH1 pathway.
     Free Radic Biol Med. 2026;244:1-16.
     Abstract
     
     
212. QASEM U, Alghwyeen W, Alshqeirat M, Saman R, et al
     Unveiling pleuropulmonary manifestations in systemic lupus erythematosus: a retrospective observational study from the Middle East.
     Clin Rheumatol. 2026;45:151-162.
     Abstract
     
     
213. HAYVACI CANBEYLI F, Secgen K, Ezgu FS, Tacoy G, et al
     The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
     Pediatr Cardiol. 2026;47:821-829.
     Abstract
     
     
214. ELSABAN M, Radosevich MA, Pennington KM, Spencer PJ, et al
     Cardiac Arrest in the Setting of Left Lung Herniation Following Combined Heart-Lung Transplant: Case Report.
     ASAIO J. 2025;71:e168-e171.
     Abstract
     
     
215. BHADRA A, Bonnie F, Hewes J, Patel M, et al
     cAMP-enriched extracellular vesicles improve outcomes in pulmonary hypertension.
     Am J Physiol Lung Cell Mol Physiol. 2026;330:L169-L177.
     Abstract
     
     
216. ZAZZERON L, Mereto E, Lichtenegger P, Moore E, et al
     Effects of continuous low-dose nitric oxide in a murine model of pulmonary hypertension with impaired lung development.
     Anesthesiology. 2026 Jan 16. doi: 10.1097/ALN.0000000000005939.
     Abstract
     
     
217. YANG JZ, Madani MM, Papamatheakis DG, Fernandes TM, et al
     CHEST How I Do It: Management of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy.
     Chest. 2026 Jan 2:S0012-3692(25)05963-X. doi: 10.1016/j.chest.2025.
     Abstract
     
     
218. CELESTIN B, Bagherzadeh SP, Santana E, Frost M, et al
     Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension.
     Chest. 2026;169:207-219.
     Abstract
     
     
219. CHANDEL A, Turkington S, King CS, Singhal A, et al
     Pulmonary hypertension prevalence and significance in lung transplant recipients with cystic fibrosis and non-cystic fibrosis bronchiectasis.
     Chest. 2026 Jan 27:S0012-3692(26)00127-3. doi: 10.1016/j.chest.2025.
     Abstract
     
     
220. ZAFEIROPOULOS S, Ahmed U, Bekiaridou A, Jayaprakash N, et al
     Correction to: Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension.
     Circ Res. 2026;138:e000740.
     Abstract
     
     
221. SHEN Y, Bisserier M
     ADAR1-Mediated RNA Editing Regulates Innate Immunity in Pulmonary Hypertension.
     Circ Res. 2026;138:e327782.
     Abstract
     
     
222. GUO S, Pan T, Yan X, Cheng Y, et al
     Differential Impact of Recruited and Resident Macrophages on Hypoxia-Induced Pulmonary Hypertension.
     Circ Res. 2025 Dec 31. doi: 10.1161/CIRCRESAHA.125.326472.
     Abstract
     
     
223. TORO V, Mougin M, Brossat C, Jambon-Barbara C, et al
     Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.
     Circulation. 2026 Jan 28. doi: 10.1161/CIRCULATIONAHA.125.079067.
     Abstract
     
     
224. TADA A, Fayyaz AU, Reddy YNV, Redfield MM, et al
     Rapidly Progressive Pulmonary Hypertension: Importance of Vascular Disease Distribution.
     Circulation. 2026;153:285-289.
     Abstract
     
     
225. BACCELLI A, Haji G, Tighe H, Howard LS, et al
     Safety of Cardiopulmonary Exercise Testing in Pulmonary Hypertension: Insights from a UK Tertiary Referral Centre.
     Eur Respir J. 2026 Jan 15:2502207. doi: 10.1183/13993003.02207-2025.
     Abstract
     
     
226. YOGESWARAN A, Kremer NC, Tello K
     Multi-beat right ventricular-pulmonary arterial coupling and survival in pulmonary hypertension: are we missing the right signals?
     Eur Respir J. 2026;67:2502501.
     Abstract
     
     
227. LIU C, Qiu BC, Li SP, Ma JS, et al
     sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension.
     Eur Respir J. 2026 Jan 22:2502367. doi: 10.1183/13993003.02367-2025.
     Abstract
     
     
228. OLLOSU M, Tripodi VF, Aresu C, Ledda G, et al
     Efficacy and Safety of Pulmonary Vasodilator and Inodilator Drugs in Congenital Heart Disease Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
     J Cardiothorac Vasc Anesth. 2026;40:333-346.
     Abstract
     
     
229. SHIGEMURA N, Hage CA
     Reframing Surgical Decision-Making When Treating Severe Pulmonary Hypertension: Beyond the Binary of Lungs Alone versus Combined Heart-Lung Transplantation.
     J Heart Lung Transplant. 2025 Dec 20:S1053-2498(25)02466.
     Abstract
     
     
230. DEWACHTER L, Vachiery JL
     Same Pressure, Different Disease: A Proteomic Rethinking of Pulmonary Hypertension in Chronic Lung Disease.
     J Heart Lung Transplant. 2026 Jan 13:S1053-2498(26)00008.
     Abstract
     
     
231. TELLO K, Delcroix M, Pausch C, Huscher D, et al
     Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.
     J Heart Lung Transplant. 2026;45:284-288.
     Abstract
     
     
232. KREMER N, Glocker F, Schaefer S, Janetzko P, et al
     Method for generating right ventricular pressure-volume loops in routine practice.
     J Heart Lung Transplant. 2026;45:273-281.
     Abstract
     
     
233. DUBROCK HM, Savale L, Sitbon O, Raevens S, et al
     International Liver Transplantation Society practice guideline update on portopulmonary hypertension.
     Liver Transpl. 2026;32:296-314.
     Abstract
     
     
234. MINATSUKI S, Hatano M, Funakoshi K, Taniguchi Y, et al
     Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension.
     Thorax. 2026 Jan 7:thorax-2025-223670. doi: 10.1136/thorax-2025-223670.
     Abstract
     
     
235. WU C, Wang Z, Luo Y, Sun H, et al
     Global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021 and projection to 2050: A systematic analysis for the global burden of disease study 2021.
     PLoS One. 2025;20:e0338335.
     Abstract